Bianka Patel, PharmD, BCOP

A panelist discusses how accessing tyrosine kinase inhibitors for chronic myeloid leukemia treatment faces multiple barriers including financial challenges from insurance coverage and rising drug costs, prior authorization requirements, social barriers like transportation and health literacy issues, and practical obstacles such as the need to manually request refills for specialty oncology medications.